Eckert & Ziegler, DE0005659700

Eckert & Ziegler stock: Berenberg maintains Buy rating

Published on 11/17/2026 at 10:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler stock traded below the previous Xetra close on Tuesday morning. Berenberg analyst Christian Ehmann continued to rate the shares Buy.

Analyst view and morning trading

  • Berenberg analyst Christian Ehmann continued to rate Eckert & Ziegler shares Buy on November 13.
  • The company recently reported stronger third-quarter operating figures and reaffirmed its 2026 targets.
  • Demand for radiopharmaceutical products and fourth-quarter license revenue remain important outlook factors.
Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Berenberg analyst Christian Ehmann continued to rate Eckert & Ziegler shares Buy on November 13, according to MarketScreener. The rating followed the company's third-quarter report and adds to the positive analyst focus on the isotope technology supplier.

Eckert & Ziegler stock traded at 15.15 euros on Lang & Schwarz at 10:00 CET on Tuesday, November 17, 2.07 percent below the Xetra close of Monday, November 16. The morning quote places the shares below the previous session's Xetra finish as investors assess the latest earnings and outlook signals.

Third-quarter recovery supports outlook

Eckert & Ziegler reported third-quarter sales of 79.6 million euros, up from 75.3 million euros a year earlier. EBIT before special items rose to 19.3 million euros from 15.4 million euros, while net income increased to 13.1 million euros from 8.5 million euros.

For the first nine months, sales reached 229.0 million euros, compared with 224.1 million euros in the prior-year period. Adjusted EBIT rose to 52.6 million euros from 50.8 million euros, and net income reached 35.4 million euros from 29.9 million euros.

The Executive Board reaffirmed its 2026 targets of around 320 million euros in sales and approximately 80 million euros in adjusted EBIT. Management expects license revenue and continued demand for radiopharmaceutical products to support the fourth quarter. The prior-year comparison also includes a licensing effect, which makes the underlying operating trend an important consideration for investors.

Berenberg's continued Buy view follows a series of constructive analyst assessments after the quarterly update. The key near-term question is whether fourth-quarter license revenue and growth in radiopharmaceutical products can deliver the earnings profile implied by the company's unchanged annual targets.

Eckert & Ziegler stock at a glance

  • Company: Eckert & Ziegler SE
  • ISIN: DE0005659700
  • Lang & Schwarz quote: 15.15 euros at 10:00 CET on November 17, 2026
  • Change versus Xetra close: 2.07 percent lower than November 16, 2026
  • Xetra close: 15.47 euros on November 16, 2026
  • Sector: Medical technology and radiopharmaceuticals

The DAX provides the relevant domestic market context for German-listed shares; current DAX market reports cover broader trading conditions.

More news and analyses on Eckert & Ziegler stock

Disclaimer...
en | DE0005659700 | ECKERT & ZIEGLER | boerse | 70525818 | bgmi